Market capitalization | $65.95m |
Enterprise Value | $131.14m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.76 |
P/S ratio (TTM) P/S ratio | 2.90 |
P/B ratio (TTM) P/B ratio | 1.42 |
Revenue growth (TTM) Revenue growth | 26.68% |
Revenue (TTM) Revenue | $22.77m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
1 Analyst has issued a forecast Celularity Inc - Ordinary Shares - Class A:
1 Analyst has issued a forecast Celularity Inc - Ordinary Shares - Class A:
Dec '23 |
+/-
%
|
||
Revenue | 23 23 |
27%
27%
|
|
Gross Profit | -2.57 -2.57 |
77%
77%
|
|
EBITDA | -67 -67 |
52%
52%
|
EBIT (Operating Income) EBIT | -76 -76 |
48%
48%
|
Net Profit | -196 -196 |
1,483%
1,483%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.
Head office | United States |
CEO | Robert Gordon |
Employees | 120 |
Founded | 2016 |
Website | www.celularity.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.